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Objectives. We examined the risk of coronary heart disease
associated with homozygosity for the C677T mutation in the
methylenetetrahydrofolate reductase gene.
Background. The mutation increases plasma homocysteine
levels by impairing its remethylation. Increased plasma homocys-
teine is an independent risk factor for cardiovascular disease.
Methods. This was a case-control study nested within the
Health Professionals Follow-up Study. In 1986, 44,940 U.S. male
health professionals, aged 40 to 75 years and free from diagnosed
cardiovascular disease, provided detailed information on usual
dietary intake, including intake of folate, vitamins B2, B6 and B12,
and methionine. Between 1993 and 1995, blood samples were
provided by approximately 40% of the participants. We compared
data from 500 men with nonfatal coronary heart disease, diag-
nosed between 1986 and 1992, with data from 500 age-matched
control subjects who were free of diagnosed cardiovascular dis-
ease at the time of the matched case subject’s diagnosis.
Results. Frequencies of homozygosity (1/1) and heterozygosity
(1/2) for the mutation were 12.2% and 41.8% in case subjects and
14.4% and 40.0% in control subjects. With subjects homozygous
(2/2) or heterozygous (1/2) for the wildtype allele as a reference
and matched by age, the odds ratio of coronary heart disease was
0.83 (95% confidence interval, 0.57 to 1.19) for 1/1 subjects. The
odds ratio was unchanged after adjustment for smoking and other
risk factors for coronary heart disease. Odds ratios were also
calculated within strata for intake of vitamins involved in homo-
cysteine metabolism or methionine, the metabolic precursor of
homocysteine. The 1/1 genotype was not directly associated with
risk of coronary heart disease among men with low (that is, within
the lowest quartile) intake (<301 mg/d) of folate, the substrate for
methylenetetrahydrofolate reductase; low intake (<1.8 mg/d) of
vitamin B2, the cofactor for methylenetetrahydrofolate reductase;
low intake (<8.0 mg/d) of vitamin B12, the cofactor for remethy-
lation; low intake (<2.1 mg/d) of vitamin B6, the cofactor in the
catabolic pathway of homocysteine; or high intake (>2.4 g/d) of
methionine.
Conclusions. In this generally well-nourished population, men
with the 1/1 genotype for the C677T mutation in the methyl-
enetetrahydrofolate reductase gene have no increase in risk of
coronary heart disease, even when intake of folate or other B
vitamins is low.
(J Am Coll Cardiol 1998;32:353–9)
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The vitamin B2-dependent enzyme methylenetetrahydrofolate
reductase (MTHFR) forms 5-methyltetrahydrofolate by reduc-
ing 5,10-methylenetetrahydrofolate, which is derived from
dietary folate. 5-Methyltetrahydrofolate provides a methyl
group for remethylation of the amino acid homocysteine to
methionine, a vitamin B12-dependent reaction (1). Increased
plasma total homocysteine level is associated with increased
risk of vascular disease of the coronary, cerebral and periph-
eral vessels (2,3). Reduced activity of MTHFR increases
homocysteine levels and consequently has been postulated to
be a risk factor for vascular disease (4). Complete MTHFR
deficiency is rare and results in hyperhomocysteinemia and
premature cardiovascular disease (CVD) (5). A less severe
genetic disorder that leads to thermolability of MTHFR was
described by Kang et al. (6,7). The presence of thermolabile
MTHFR was associated with increased total homocysteine
levels and carries a higher risk of coronary artery disease
(8–10). Recently, Frosst et al. (11) identified a missense
mutation in which a cytosine residue at position 677 of the
MTHFR gene is replaced by thymine. The mutation results in
a substitution of alanine by valine, and persons homozygous for
the mutation have decreased specific MTHFR activity and
increased thermolability of the enzyme (11). Persons heterozy-
gous for the gene have a specific MTHFR activity intermediate
between the two homozygous groups (11). However, only 1/1
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homozygous subjects have increased total homocysteine levels,
20% to 30% higher than subjects with the homozygous normal
genotype (11–14). This finding is most apparent in subjects
with low folate status (12,13,15). Several epidemiologic studies
investigated the association between the C677T mutation and
risk of CVD; most used coronary heart disease (CHD) as an
end point and obtained contradictory results (13,14,16–31).
In the present investigation among 500 case subjects and
500 control subjects in the Health Professionals Follow-up
Study, we studied risk of CHD associated with homozygosity
for the mutation. We investigated whether the effect of the
mutation could be moderated by dietary folate and various
other factors that might affect homocysteine or folate metab-
olism, including age, and intake of vitamins B2, B6, B12,
methionine (the metabolic precursor of homocysteine), and
alcohol. We hypothesized that homozygosity for the mutation
would be a stronger risk factor for CHD in subgroups with low
vitamin intake levels (particularly low folate intake), high
methionine intake, and high alcohol consumption (because of
its effects on folate metabolism).
Methods
The Health Professionals Follow-Up Study. In 1986 this
study prospectively investigated 51,529 male health profession-
als, 40 to 75 years old, who completed a comprehensive mailed
questionnaire on dietary and exercise habits. Follow-up ques-
tionnaires were mailed in 1988, 1990, and 1992 to ascertain
newly diagnosed coronary events (32).
On the basis of a priori criteria we excluded 1,595 men
whose reported daily energy intake was outside the range of
3,360 to 17,640 kJ or who left blank 70 or more items about
food in the dietary questionnaire. Because men with CVD or
related conditions may have recently changed their dietary
pattern in response to diagnosis, we further excluded 4,994
men who reported CVD on the baseline 1986 questionnaire,
leaving 44,940 men for follow-up.
Blood collection. In 1992, we sent a blood collection kit to
each participant who was willing to provide a specimen.
Participants were asked to return three 10-ml vials of whole
blood. Between 1993 and 1995 we received blood samples from
18,025 participants. Upon arrival, the specimens were centri-
fuged at 4°C to obtain plasma, serum, and buffy coat. These
samples were stored at 2150°C in liquid nitrogen.
Case ascertainment and control identification. We se-
lected subjects who had provided blood samples and in whom
CHD had been diagnosed (either myocardial infarction, coro-
nary artery bypass grafting [CABG], or percutaneous translu-
minal coronary angioplasty [PTCA]) after return of the base-
line 1986 questionnaire but before January 31, 1992. The men
reported the diagnosis on the follow-up questionnaires of 1988,
1990, or 1992. We requested medical records from a sample of
participants who reported CABG or PTCA. In a sample of 102
self-reported events, 98 (96%) were confirmed by medical
record, so we accepted self-report of all other CABGs or
PTCAs as CHD end points. A myocardial infarction was
confirmed by a study physician using the following World
Health Organization criteria: compatible symptoms plus either
typical electrocardiographic changes or elevation of cardiac
enzymes (33). We identified 500 cases of nonfatal CHD, 220
with myocardial infarction and 280 with either CABG or
PTCA. Because the blood samples were collected after diag-
nosis, we could not include fatal cases. One control subject was
matched to each case subject by age (61 year). Control
subjects were randomly selected from participants who had
also provided a blood sample, met the matching criteria and
were free from clinical CHD at the time of diagnosis in the
matched case subject.
Dietary assessment. The 1986 questionnaire inquired
about average intake of 131 foods during the previous year. In
addition to the structured questions on food intake, we asked
participants to identify specific brands of cold breakfast cere-
als, multivitamins, and cooking oils. Average intake of methi-
onine, folate, and vitamins B2, B6 and B12 was computed by
multiplying the frequency of consumption of each food item by
the nutrient content of the listed portion size (34). Intake from
vitamin supplements was factored into average intake. We
used food composition tables from U.S. Department of Agri-
culture sources (35) with supplementary information provided
by collaborating laboratories and other publications. We ad-
justed all dietary intakes for total energy intake by using
regression analysis (36). In 1987, the precision of nutrient
consumption measured by the questionnaire was evaluated in
a subsample of 127 participants from the Boston area (34). In
brief, these men completed two 1-week dietary records and
provided a fasting blood sample. Mean daily intake of nutri-
ents, including folate, vitamins B2, B6 and B12, as assessed by
the questionnaire and the dietary records were very similar,
and the correlations between the two methods were 0.71 for
folate, 0.85 for vitamin B2, 0.82 for vitamin B6, and 0.50 for
vitamin B12. Data on methionine intake were not available
from diet records. The correlation between folate intake as
determined by the questionnaire and erythrocyte folate from
the blood samples was 0.55 (with deattenuation for within-
person variability in the blood level) (37). In a subpopulation
of elderly in the Framingham study (38), in which the same
dietary questionnaire was used, the correlation between folate
intake and plasma folate concentration was 0.63. In that same
study, the correlation between intake of vitamin B6 and plasma
pyridoxal-59-phosphate was 0.39 (39) and the correlation be-
tween vitamin B12 intake and plasma vitamin B12 was 0.35 (38).
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CHD 5 coronary heart disease
CI 5 confidence interval
CVD 5 cardiovascular disease
MTHFR 5 methylenetetrahydrofolate reductase
OR 5 odds ratio
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DNA analysis for MTHFR mutation. We use the notations
“1” and “2” to refer to alleles with and without the mutation,
respectively. Thus, homozygosity for the mutation is denoted
as 1/1, heterozygosity as 1/2, and homozygosity for the wild
type as 2/2.
We extracted DNA from the buffy coat specimens. Geno-
typing for MTHFR was carried out using a modification (40) of
the polymerase chain reaction–restriction fragment length
polymorphism assay of Frosst et al. (11). The sequence change
of cytosine to thymine results in a gain of a Hinfl restriction
site. Polymerase chain reaction amplification was followed by
Hinfl digestion, and restriction fragments were size-fractioned
on polyacrylamide gels. The 198-bp polymerase chain reaction
fragment was digested into 175-bp and 23-bp fragments; the
latter fragment ran off the gel. As a result, there was one
198-bp band for the 2/2 genotype, 198-bp and 175-bp bands
for the 1/2 genotype and one 175-bp band for the 1/1
genotype. Genotype results were scored without reference to
case-control status. If there was any ambiguity, the polymerase
chain reaction, Hinfl digestion, and scoring were repeated.
Approximately 10% of the samples were quality control
specimens. We selected an equal number of samples known to
be of the 1/1 genotype, the 1/2 genotype and the 2/2
genotype (four of each) and randomly, repeatedly placed them
throughout the batches to total 10% of the samples.
Statistical analysis. Differences in coronary risk factors
between case and control subjects were tested for significance
by a paired Student’s t test for continuous variables and a
McNemar paired chi-square test for categorical variables. The
association of MTHFR genotype with risk of CHD was
evaluated by calculating odds ratios (ORs) and 95% confi-
dence intervals (CIs) for 1/1 genotype, using conditional
logistic regression analysis. Odds ratios were also calculated
with unconditional logistic regression analysis, disregarding the
pair matching for age, but with age as a covariate in the model.
We present ORs for 1/2 and 1/1 genotypes, with 2/2
genotype as the reference, and for 1/1 subjects with both
other genotypes as the reference. The unmatched risk analyses
were repeated for cases of coronary artery disease (that is, all
subjects with CABG or PTCA) and cases of myocardial
infarction separately, because CABG and PTCA may repre-
sent atherosclerotic heart disease and myocardial infarction
(athero)thrombotic heart disease. Furthermore, we performed
risk analyses for CHD with presence or absence of one or more
conventional risk factors for CHD (smoking, hypertension,
hypercholesterolemia). In addition, we calculated ORs for
1/1 subjects versus 1/2 or 2/2 subjects, within strata of
dietary folate and other factors that may affect folate or
homocysteine metabolism, such as age, alcohol consumption
and dietary intake of methionine, and vitamins B2, B6 and B12.
The three strata of each of these factors were based on quartile
boundaries of the total population (#25th percentile, 26th to
75th percentile and .76th percentile). All p values are two
sided.
Results
Risk factors for coronary artery disease and other charac-
teristics at baseline are shown in Table 1. Case subjects had a
higher mean body mass index, were more often current
smokers and had a higher frequency of history of hypertension,
hypercholesterolemia, diabetes and familial history of myocar-
dial infarction.
Table 2 shows genotype frequencies for case and control
subjects separately. Frequencies of the various genotypes were
similar and were in Hardy-Weinberg equilibrium in both case
and control subjects. Compared to the other two genotypes
combined, homozygosity for the mutation was slightly and
nonsignificantly (p 5 0.31) more common among control
subjects than case subjects. When 2/2 genotype was consid-
ered as a reference, the age-matched OR for 1/1 genotype
was 0.84 (95% CI 0.57 to 1.23); 1/2 subjects had an OR of
1.04 (95% CI 0.80 to 1.37). When 2/2 and 1/2 subjects were
considered as a single reference group, the age-matched OR
for 1/1 genotype was 0.83 (95% CI 0.57 to 1.19). The
Table 1. Characteristics of 500 Cases of Nonfatal Coronary Heart Disease and 500 Age-matched





(n 5 500) p Value*
Age (yr) 58.9 6 7.8 58.9 6 7.9
Currently smoking (%) 10.8 6.4 0.02
Body mass index (kg/m2) 26.2 6 3.1 25.6 6 3.1 0.002
Alcohol consumption (g/d) 11.7 6 17.2 13.0 6 17.4 0.25
Calorie intake (kcal/d) 1964 6 616 1983 6 577 0.60
History of high cholesterol (%) 19.0 10.2 ,0.001
History of hypertension (%) 32.6 19.8 ,0.001
History of diabetes (%) 5.8 2.8 0.02




*Tested with a paired Student t test for continuous variables and McNemar chi-square test for frequencies. MI 5
myocardial infarction.
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unmatched ORs (Table 2), with age as a covariate, were similar
to the age-matched ORs.
There were no statistically significant differences in mean
levels or frequencies of coronary risk factors among the
genotypes or a trend of any kind. Thus, inclusion of smoking,
hypertension, hypercholesterolemia, body mass index, alcohol
intake, diabetes, multivitamin use and family history of myo-
cardial infarction as covariates in the multivariately adjusted
logistic regression model did not affect the ORs (Table 2).
Controlling for family history of myocardial infarction may be
considered over-controlling when studying a genetic risk fac-
tor, but exclusion of this factor from the multivariate model did
not change results. Homozygosity for the mutation was not
more common among subjects with a positive family history of
myocardial infarction.
In all subsequent risk analyses, we considered 2/2 and
1/2 genotypes as one reference group, because the risk of
CHD in subjects with 1/2 genotype was not higher and
because 1/2 and 2/2 groups had plasma total homocysteine
levels similar to those in other studies (11,13).
Because pathophysiologic mechanisms may differ between
subjects with coronary artery disease (that is, persons who have
undergone CABG or PTCA) and subjects who have had a
myocardial infarction, we repeated the calculations of the ORs
for 1/1 genotype in these subgroups of cases, using all control
subjects in both analyses and taking 2/2 and 1/2 genotypes
as the reference group. The OR for coronary artery disease
was 1.04 (95% CI 0.69 to 1.58) and for myocardial infarction
was 0.55 (95% CI 0.32 to 0.95) after adjustment for age. When
controlling for other risk factors of CHD, these ORs were 1.04
(95% CI 0.67 to 1.62) and 0.49 (96% CI 0.28 to 0.87),
respectively.
Similarly, we conducted separate analyses for CHD with or
without the presence of various risk factors for coronary artery
disease (current smoking, hypertension, hypercholesterol-
emia), including all control subjects in both subanalyses.
Controlling for age, the ORs for 1/1 genotype versus 1/2 and
2/2 genotypes were 0.82 (95% CI 0.52 to 1.29) for nonfatal
CHD without presence of current smoking, hypertension or
hypercholesterolemia (256 cases) and 0.82 (95% CI 0.52 to
1.30) for nonfatal CHD with presence of one or more of the
risk factors (244 cases). Additional adjustment for other fac-
tors, (body mass index, alcohol intake, diabetes, multivitamin
use and family history of myocardial infarction) did not change
the ORs.
Finally, we calculated ORs for the 1/1 genotype versus the
2/2 or 1/2 genotypes within strata of dietary folate level and
several other factors that might affect homocysteine or folate
metabolism (Table 3). The OR for 1/1 genotype was not
higher in any of the strata where an increased risk for 1/1
genotype might be expected, eg, low intake of folate or other
vitamins, high intake of methionine, younger age or high
alcohol consumption.
Discussion
Strengths and limitations of present study. In the Health
Professionals Follow-up Study, we found no increased risk of
nonfatal CHD among men homozygous for the C677T muta-
tion in the MTHFR gene, even among those with low intake of
folate. When myocardial infarction and coronary artery disease
(CABG and PTCA) were considered as separate end points,
we found a statistically significant inverse association for
myocardial infarction and no association with CABG and
PTCA, possibly a chance finding.
A limitation of the present study was that we did not
measure plasma homocysteine concentrations. It is possible
that men homozygous for the MTHFR C677T mutation had
normal homocysteine concentrations, which would explain the
absence of an association between genotype and risk of CHD.
However, in the Physicians’ Health Study (13), a population
comparable to the present one in age, gender, occupation and
frequency of vitamin supplement use, mean plasma total
homocysteine levels were 2 to 4 mmol/l higher in subjects with
1/1 genotype than the 2/2 or 1/2 genotype. Differences of
this magnitude were also observed in other studies (11,14). On
the basis of a large meta-analysis (2), for this difference in
plasma homocysteine levels, an OR of about 1.5 for CHD
would be expected for the 1/1 genotype compared with the
other genotypes. The CI for our overall estimate excludes this
value, but it is included in the CI for the coronary artery
disease end point. Thus, our study suggests that the 1/1
Table 2. Frequency of Methylenetetrahydrofolate Reductase Genotype and Odds Ratios of Nonfatal
Coronary Heart Disease Among 500 Case and 500 Control Subjects
MTHFR
Genotype
Cases Controls Odds Ratio (95% CI)
n (%) n (%) Age-Adjusted* Multivariate-Adjusted†
2/2 230 (46.0) 228 (45.6) 1.00 1.00
1/2 209 (41.8) 200 (40.0) 1.03 (0.79 to 1.35) 1.01 (0.76 to 1.33)
1/1 61 (12.2) 72 (14.4) 0.84 (0.57 to 1.23) 0.82 (0.55 to 1.24)
0.82 (0.57 to 1.19)‡ 0.82 (0.56 to 1.20)‡
*With 2/2 genotype as reference group; adjusted for age, using unconditional logistic regression analysis. †With 2/2
genotype as reference group; adjusted for age, smoking, body mass index, family history of myocardial infarction, current
use of multivitamin supplements, alcohol consumption, calorie intake, history of high cholesterol, hypertension and
diabetes, using unconditional logistic regression analysis. ‡With 2/2 and 1/2 genotypes as one reference. CI 5 95%
confidence interval; MTHFR 5 methylenetetrahydrofolate reductase.
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genotype for the C677T mutation does not confer an increased
risk of CHD, although we cannot completely eliminate a small
increase in risk of coronary atherosclerosis.
We considered that only men who survived until 1995 could
provide blood samples. If CHD in subjects with 1/1 genotype
was more often fatal, then these subjects might be underrep-
resented in our population, which could in part explain an
inverse association. However, fatality because of CHD was low
(18%) in case subjects. Thus, only an extremely strong rela-
tionship between genotype and case fatality could obscure a
true OR of 1.5. We have no reason to believe that the
relationship between increased plasma homocysteine level
differs for incident cases of fatal and nonfatal CHD; in the
Physicians’ Health Study results were similar for fatal and
nonfatal myocardial infarction (Ma J, personal communica-
tion, July 1997).
The 1/1 genotype was not associated with risk of CHD in
men with no conventional risk factors, men younger than 55
years, men with low intake of folate, vitamin B2, vitamin B12
(coenzyme for remethylation of homocysteine to methionine)
or vitamin B6 (coenzyme in catabolic pathway of homocysteine
metabolism). The present study examined the interaction
between MTHFR genotype and prospectively measured folate
intake. Homozygosity for the mutation was associated with
reduced plasma folate concentration (13,41); therefore, exam-
ining dietary folate is directly advantageous. The detailed food
frequency questionnaire measures dietary intake of folate and
other B vitamins moderately accurately (35) and correlates
with measures of folate status, such as erythrocyte (37) and
plasma folate levels (38), thus reducing the chance that we
missed any important effect modification. However, this study
population is generally well nourished, and an association
might be seen with folate intake level less than the lowest
quartile of this group.
Comparison with results from other studies. Several stud-
ies have investigated the relation between the MTHFR C677T
mutation and risk of CVD, with most having CHD as the
disease end point of interest (13,14,16–31). In five of these
studies (14,17,18,24,29), a direct association was observed, with
ORs for the 1/1 genotype between 2 and 3, whereas the other
studies found no association between this common mutation
and risk of CVD. In the studies that observed direct associa-
tion between the mutation and risk of CVD, patients with
early-onset CVD (as expected for a genetically-determined
risk factor) were more likely to be included, although other
studies of premature cardiovascular disease did not find an
association. Another possible explanation for the direct asso-
ciation in those five studies might be a lower status of vitamins
involved in homocysteine metabolism, especially folate. In
Europe as opposed to the United States, use of vitamin
supplements and fortification of food products with folic acid is
uncommon. For comparison, in a large population-based sam-
ple of Irish men (12), mean serum folate level was approxi-
mately 11 nmol/l, whereas mean plasma levels of 14 and 15
nmol/l are reported in U.S. populations (15,25). Similarly, the
increased risk in the two Japanese studies (18,29) may be
related to the relatively low intake of vitamin B2 (coenzyme for
MTHFR) because of low consumption of milk and milk
products.
Concluding remarks. There are several possible explana-
tions for the absence of a positive association between 1/1
genotype and risk of CHD. It is possible that homocysteine
concentrations were not increased in subjects with the 1/1
genotype. However, homocysteine concentration is generally
higher among those with the 1/1 genotype, as well as in
well-nourished populations, such as that of the Physicians’
Health Study (13). Therefore, our findings may also indicate
that higher plasma total homocysteine level is not itself a risk
factor for CHD but a marker of low folate status, which may
independently affect risk of CHD. However, two factors weigh
against this explanation, plausible atherothrombotic effects of
homocysteine (42) and the possibility that the 1/1 genotype
increases risk in populations with a lower folate status.
Table 3. Odds Ratios of Nonfatal Coronary Heart Disease for 1/1
Methylenetetrahydrofolate Reductase Genotype versus 1/2 or 2/2
Genotype, Stratified by Age, Alcohol Consumption, Intake of





Odds Ratio (95% CI)
Age (yr)
,55 0.87 (0.43 to 1.76) 0.92 (0.43 to 1.97)
55–64 0.59 (0.34 to 1.04) 0.70 (0.38 to 1.27)
.64 1.31 (0.66 to 2.61) 1.02 (0.49 to 2.12)
Alcohol consumption (g/d)
,1.0 0.52 (0.25 to 1.11) 0.49 (0.22 to 1.10)
1.0–16.7 1.01 (0.60 to 1.68) 1.04 (0.60 to 1.83)
.16.7 0.68 (0.31 to 1.51) 0.60 (0.24 to 1.47)
Folate intake (mg/d)
,301 0.66 (0.30 to 1.46) 0.75 (0.32 to 1.75)
302–595 1.00 (0.59 to 1.67) 0.91 (0.52 to 1.59)
.595 0.68 (0.32 to 1.44) 0.72 (0.32 to 1.59)
Vitamin B12 intake (mg/d)
,8.0 1.06 (0.56 to 2.01) 1.05 (0.52 to 2.12)
8.0–14.0 0.66 (0.37 to 1.19) 0.61 (0.33 to 1.15)
.14.0 0.81 (0.39 to 1.69) 0.78 (0.33 to 1.83)
Vitamin B2 intake (mg/d)
,1.8 0.59 (0.28 to 1.25) 0.55 (0.24 to 1.25)
1.8–3.6 0.85 (0.51 to 1.43) 0.87 (0.50 to 1.52)
.3.6 0.94 (0.44 to 2.00) 0.92 (0.39 to 2.14)
Vitamin B6 intake (mg/d)
,2.1 0.51 (0.24 to 1.12) 0.56 (0.24 to 1.30)
2.1–4.2 0.95 (0.57 to 1.58) 0.96 (0.55 to 1.68)
.4.2 0.90 (0.42 to 1.93) 0.84 (0.37 to 1.91)
Methionine (g/d)
,2.0 0.63 (0.30 to 1.34) 0.64 (0.28 to 1.44)
2.0–2.4 0.94 (0.56 to 1.58) 0.97 (0.56 to 1.68)
.2.4 0.82 (0.38 to 1.76) 0.81 (0.35 to 1.91)
*Adjusted for age (crude odds ratio is shown within the stratum of age).
†Adjusted for age (with exception of the stratum of age), smoking, body mass
index, family history of myocardial infarction, current use of multivitamin
supplements, alcohol consumption (with exception of the strata of alcohol
consumption), calorie intake, history of high cholesterol, hypertension and
diabetes, with 2/2 and 1/2 genotypes as reference group. CI 5 confidence
interval.
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We found no evidence that men with the 1/1 genotype for
the C677T mutation in the MTHFR gene are at increased risk
of nonfatal CHD, even among those with folate or other
B-vitamin intake lower than the 25th percentile. The well-
nourished condition of the study population might contribute
to this finding. Our results of a decreased risk of nonfatal
myocardial infarction are most likely a chance finding but
introduce the possibility of a beneficial effect of the mutation.
If the results of all other epidemiologic studies are considered,
it is unlikely that the C677T mutation is an important risk
factor for CHD in particular and cardiovascular disease in
general.
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